CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs ...
1hon MSN
Dragons' Den for doctors: this competition takes scientists' pitches on how to improve health care
From AI innovations to new medical devices, a research competition at St. Michael's Hospital aims to bring to life ideas that ...
Asianet Newsable on MSN
CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast?
CorMedix said it was raising its fiscal 2025 pro forma net revenue guidance to at least $375 million. The company said the ...
CRMD, CELC, RANI, and RAPT are pushing aggressively to the upside on Monday. Here's what is driving these four biotech stocks ...
21h
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
Based on the current sales trend for DefenCath as well as the performance of the recently acquired Melinta portfolio, CorMedix is increasing its full-year 2025 pro forma net revenue guidance from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback